Mengke Niu

发表

CD44 as a tumor biomarker and therapeutic target

Kongming Wu, Aiguo Liu, Hanxiao Xu, 2020, Experimental Hematology & Oncology.

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Anping Li, Kongming Wu, Mengke Niu, 2021, Journal of Hematology & Oncology.

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

Kongming Wu, Mengke Niu, Ming Yi, 2022, Molecular Cancer.

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Kongming Wu, D. Jiao, Mengke Niu, 2022, Journal of Hematology & Oncology.

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer

Mengke Niu, Ming Yi, Yuze Wu, 2022, Journal for ImmunoTherapy of Cancer.

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Kongming Wu, Mengke Niu, H. Ge, 2022, Molecular cancer.

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Kongming Wu, Mengke Niu, Ming Yi, 2021, Experimental Hematology & Oncology.

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer

Kongming Wu, D. Jiao, Mengke Niu, 2022, Frontiers in Immunology.

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Kongming Wu, Mengke Niu, Ming Yi, 2022, Frontiers in Immunology.

Regulation of PD-L1 expression in the tumor microenvironment

Kongming Wu, Linping Xu, Mengke Niu, 2021, Journal of Hematology & Oncology.

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Kongming Wu, Mengke Niu, Ming Yi, 2021, Journal of Hematology & Oncology.

Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study

Kongming Wu, Mengke Niu, Ming Yi, 2021, Biomarker research.

Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells

B. Dong, Kongming Wu, Mengke Niu, 2020, Annals of translational medicine.

Advances of Targeted Therapy for Hepatocellular Carcinoma

Mengke Niu, Ming Yi, Ning Li, 2021, Frontiers in Oncology.

Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study

Mengke Niu, S. Luo, Ning Li, 2021, Cancer management and research.

Increased expression of ECT2 predicts the poor prognosis of breast cancer patients

Kongming Wu, B. Song, Mengke Niu, 2022, Experimental Hematology & Oncology.

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Xinrun Wang, Jianwei Zhou, Kongming Wu, 2023, Frontiers in immunology.

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy

Jing Zhang, Lijuan Lyu, Mengke Niu, 2023, Journal of Hematology & Oncology.

Exploiting innate immunity for cancer immunotherapy

Mengke Niu, Ming Yi, Kongming Wu, 2023, Molecular Cancer.

CAR-NK cells for cancer immunotherapy: recent advances and future directions

Mengke Niu, Weijiang Zhang, Ming Yi, 2024, Frontiers in immunology.

Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors

Mengke Niu, Ming Yi, Kongming Wu, 2024, Cancer communications.

Targeting cytokine and chemokine signaling pathways for cancer therapy

Mengke Niu, Kongming Wu, Zhi-tang Dai, 2024, Signal transduction and targeted therapy.

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

Mengke Niu, Ming Yi, Kongming Wu, 2024, Cell communication and signaling : CCS.

S100A8/A9 as a risk factor for breast cancer negatively regulated by DACH1

Mengke Niu, Ming Yi, Kongming Wu, 2023, Biomarker research.